GE HealthCare Q2 Earnings & Sales Beat Estimates, Net Margin Rises

GE HealthCare GEHC reported second-quarter 2025adjusted earnings per share (EPS) of $1.06, which beat the Zacks Consensus Estimate of 91 cents by 16.5%. Also, the bottom line improved 6% year over year.GAAP EPS in the quarter was also $1.06, up 13.9% from the year-ago level.Revenue DetailsThe company reported revenues of $5 billion, up 3% year over year on a reported basis and 2% organically. The top line beat the Zacks Consensus Estimate by 0.1%. Total company orders increased 3% organically year over year.Revenues were driven by strength in the U.S. market across all segments, especially in the Imaging and Pharmaceutical Diagnostics segments.Segmental DetailsImagingRevenues from this segment totaled $2.2 billion, up 2% year over year on a reported basis and 1% organically.Segment EBIT was $188 million, down 10% year over year.Advanced Visualization SolutionsRevenues totaled $1.29 billion, up 3% year over year on a reported basis and 2% on an organic basis.Segment EBIT was $267 million, up 4% year over year.Patient Care SolutionsRevenues amounted to $778 million, up 1% year over year on a reported basis and flat organically.Segment EBIT was $60 million, down 23% year over year.Pharmaceutical DiagnosticsRevenues totaled $729 million, up 14% year over year and 5% on an organic basis.Segment EBIT was $213 million, up 7% year over year.GE HealthCare Technologies Inc. Price, Consensus and EPS Surprise GE HealthCare Technologies Inc. price-consensus-eps-surprise-chart | GE HealthCare Technologies Inc. QuoteMarginsNet income margin was 9.7%, up 80 basis points from the prior-year level, primarily attributable to benefits from productivity and pricing.Cumulative cash flow from operating activities at the end of the second quarter was $344 million compared with $300 million a year ago.Financial PositionGEHC exited the second quarter with cash, cash equivalents and investments of $3.76 billion compared with $2.47 billion in the previous quarter.Total assets increased to $35.5 billion from $33.59 billion on a sequential basis.2025 GuidanceGE HealthCare raised its earnings and organic revenue guidance for 2025.The company now expects adjusted EPS in the range of $4.43-$4.63, up from $3.90-$4.10 expected previously. The guide includes approximately 45 cents of unfavorable impact of tariffs. Revenues are now anticipated to grow 3% organically, up from 2-3% expected previously and therefore reflecting continued demand for its products and services. The Zacks Consensus Estimate for 2025 EPS and revenues is pegged at $4.02 and $20.31 billion, respectively.Zacks Rank and Stocks to ConsiderGEHC carries a Zacks Rank #3 (Hold) at present.Some better-ranked stocks in the broader medical space that have announced quarterly results are Medpace Holdings, Inc. MEDP, West Pharmaceutical Services, Inc. WST and Boston Scientific Corporation BSX.Medpace Holdings, sporting a Zacks Rank of 1 (Strong Buy), reported second-quarter 2025 EPS of $3.10, beating the Zacks Consensus Estimate by 3.3%. Revenues of $603.3 million outpaced the consensus mark by 11.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%.West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, beating the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1.West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2 (Buy).Boston Scientific has a long-term estimated growth rate of 14%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%.#1 Semiconductor Stock to Buy (Not NVDA)The incredible demand for data is fueling the market's next digital gold rush. As data centers continue to be built and constantly upgraded, the companies that provide the hardware for these behemoths will become the NVIDIAs of tomorrow.One under-the-radar chipmaker is uniquely positioned to take advantage of the next growth stage of this market. It specializes in semiconductor products that titans like NVIDIA don't build. It's just beginning to enter the spotlight, which is exactly where you want to be.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX): Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST): Free Stock Analysis Report Medpace Holdings, Inc. (MEDP): Free Stock Analysis Report GE HealthCare Technologies Inc. (GEHC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks